PCSK9: the Critical Role of Familial Hypercholesterolemia from Discovery to Benefit for all : Editorial to: "Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/Dl or Higher" by Henry N. Ginsberg et Al.
Metabolic and Atherosclerosis Research Center, Cincinnati, OH, USA. esteinmrl@aol.com.
Evan A
EA
Stein
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000924:Anticholesteremic Agents / Q000627:therapeutic use; D008078:Cholesterol, LDL; D006801:Humans; D006937:Hypercholesterolemia / Q000188:drug therapy; D006938:Hyperlipoproteinemia Type II / Q000188:drug therapy*; D043484:Proprotein Convertases; D012697:Serine Endopeptidases
D000911:Antibodies, Monoclonal; D000924:Anticholesteremic Agents; D008078:Cholesterol, LDL; D043484:Proprotein Convertases; D012697:Serine Endopeptidases